Inactive Instrument

ADVANZ PHARMA Corp. Limited

CXRXF

JE00BJVH6L55

Advanz Pharma Corp. Limited Reports Earnings Results for the Full Year Ended December 31, 2020

March 17, 2021 at 06:25 pm EDT

ADVANZ PHARMA Corp. Limited announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was USD 525.584 million compared to USD 508.321 million a year ago. Operating loss was USD 5.309 million compared to USD 140.034 million a year ago. Net loss was USD 74.858 million compared to USD 196.018 million a year ago. Basic loss per share from continuing operations was USD 1.53 compared to USD 4.01 a year ago.

Latest news about ADVANZ PHARMA Corp. Limited

ADVANZ PHARMA Corp. Limited announced that it has received funding from Nordic Capital, Ontario Teachers' Pension Plan Board	Feb. 25	CI
ADVANZ PHARMA Corp. Limited signed an agreement to acquire Global rights of Androcur.	Nov. 06	CI
ADVANZ PHARMA Corp. Limited completed the acquisition of Global rights of Tostran from Kyowa Kirin Co., Ltd..	23-10-17	CI
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe	23-05-24	CI
ADVANZ PHARMA Corp. Limited signed an agreement to acquire Global rights of Tostran from Kyowa Kirin Co., Ltd..	23-04-24	CI
Applied Therapeutics, Inc. Announces Partnership with Advanz Pharma for Commercialization of AT-007 in Europe	23-01-04	CI
ADVANZ PHARMA Corp. Limited acquired Portfolio Of Generic Drugs Of Sanofi.	22-10-02	CI
ADVANZ PHARMA Corp. Limited Names Andreas Stickler as New CFO	22-04-01	CI
ADVANZ PHARMA Corp. Limited Limited Names Susanna El-Armale as Chief Corporate Development Officer	22-04-01	CI
Steffen Wagner Assumes His Position as New Chief Executive Officer At ADVANZ PHARMA Corp. Limited	22-04-01	CI
ADVANZ PHARMA Corp. Limited Announces Executive Changes	21-11-18	CI
ADVANZ PHARMA Corp. Limited Announces Executive Changes	21-11-18	CI
ADVANZ PHARMA Corp. Limited Announces Executive Changes	21-11-18	CI
ADVANZ PHARMA : Nordic Capital Completes US$846 Million Acquisition of Advanz Pharma	21-06-01	MT
Nordic Capital completed the acquisition of ADVANZ PHARMA Corp. Limited (OTCPK:CXRX.F) from a group of shareholders.	21-05-31	CI
ADVANZ PHARMA Corp. Limited Announces Earnings Results for the First Quarter Ended March 31, 2021	21-05-14	CI
Advanz Pharma Corp. Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-17	CI
ADVANZ PHARMA Corp. Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020	21-03-17	CI
ADVANZ PHARMA Corp. Limited (OTCPK:CXRX.F) acquired Global Rights to Cyclophosphomide from Zenex Pharmaceuticals Pty Ltd for AUD 0.01 million.	21-01-28	CI
Nordic Capital entered into a scheme of agreement to acquire ADVANZ PHARMA Corp. Limited (OTCPK:CXRX.F) from a group of shareholders for approximately $870 million.	21-01-26	CI
ADVANZ PHARMA : Correction to Drugmakers Raise Prices Article of Jan. 1	21-01-08	DJ
Advanz Pharma Corp. Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-06	CI
Transcript : ADVANZ PHARMA Corp. Limited, Q3 2020 Earnings Call, Nov 06, 2020	20-11-06
ADVANZ PHARMA Provides Earnings Guidance for the Fourth Quarter of 2020	20-11-06	CI
ADVANZ PHARMA : Earnings Flash (CXRXF) ADVANZ PHARMA Posts Q3 Revenue $128.7M	20-11-06	MT

Chart ADVANZ PHARMA Corp. Limited

Duration

Period

More charts

Company Profile

ADVANZ PHARMA Corp. Limited is a United Kingdom-based pharmaceutical company. It is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. The Company is focused on investing in product portfolio to optimize healthcare treatment. Its therapy areas include endocrinology, ophthalmology, urology, anti-infectives, pain management, central nervous system disorders and intensive care medicines. The Company optimizes healthcare treatment through product acquisitions, in-licensing opportunities, product development and alliances worldwide. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products and operates facilities in various locations, including Sydney, Australia; Mumbai, India; Dublin, Ireland; St. Helier, Jersey; Helsingborg, Sweden, and Chicago, United States.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+34.02%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.66%	354B
MERCK & CO., INC.	+18.44%	330B
ABBVIE INC.	+4.92%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.64%	148B

Other Pharmaceuticals